NCT02004106View on ClinicalTrials.gov

A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Neoplasms
Interventions
DRUG

RO6895882

Participants will receive RO6895882 at different dose levels and schedules defined in respective arms as IV infusion.

Trial Locations (10)

1011

CHUV; Departement d'Oncologie, Lausanne

2100

Rigshospitalet, Onkologisk Klinik, København Ø

10065

Memorial Sloan Kettering Cancer Center, New York

31008

Clinica Universitaria de Navarra; Servicio de oncología, Pamplona

94805

Institut Gustave Roussy; Departement Oncologie Medicale, Villejuif

00029

Helsinki University Central Hospital; Dept of Oncology, Helsinki

1066 CX

Antoni van Leeuwenhoek Ziekenhuis, Amsterdam

1081 HV

VU MEDISCH CENTRUM; Dept. of Medical Oncology, Amsterdam

08035

Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona

OX3 7LE

Oxford University Hospitals NHS Trust - Churchill Hospital, Oxford

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02004106 - A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter